World Library  
Flag as Inappropriate
Email this Article

Chlamydophila pneumoniae

Article Id: WHEBN0001709062
Reproduction Date:

Title: Chlamydophila pneumoniae  
Author: World Heritage Encyclopedia
Language: English
Subject: Chlamydiae, Chlamydophila, List of infectious diseases, Infectious causes of cancer, Atypical pneumonia
Collection: Bacteria with Sequenced Genomes, Chlamydiae, Infectious Causes of Cancer
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Chlamydophila pneumoniae

Chlamydophila pneumoniae
Scientific classification
Kingdom: Bacteria
Phylum: Chlamydiae
Order: Chlamydiales
Family: Chlamydiaceae
Genus: Chlamydophila
Species: C. pneumoniae[1]

Chlamydophila pneumoniae is a species of Chlamydophila, an obligate intracellular bacterium[2] that infects humans and is a major cause of pneumonia. It was known as the Taiwan acute respiratory agent (TWAR) from the names of the two original isolates – Taiwan (TW-183) and an acute respiratory isolate designated AR-39.[3] Until recently, it was known as Chlamydia pneumoniae, and that name is used as an alternate in some sources.[4] In some cases, to avoid confusion, both names are given.[5]

C. pneumoniae has a complex life cycle and must infect another cell to reproduce; thus, it is classified as an obligate intracellular pathogen. The full genome sequence for C. pneumoniae was published in 1999.[6] It also infects and causes disease in koalas, emerald tree boas (Corallus caninus), iguanas, chameleons, frogs, and turtles.

The first known case of infection with C. pneumoniae was a case of conjunctivitis in Taiwan in 1950. This atypical bacterium commonly causes pharyngitis, bronchitis and atypical pneumonia in addition to several other possible diseases.[7][8]

Micrograph ofChlamydophila (Chlamydia) pneumoniae in an epithelial cell in acute bronchitis: 1 – infected epitheliocyte, 2 – uninfected epitheliocytes, 3 – chlamydial inclusion bodies in cell, 4 – cell nuclei

Contents

  • Life cycle and method of infection 1
  • Diseases 2
  • Vaccine research 3
  • References 4
  • External links 5

Life cycle and method of infection

Life cycle of Chlamydophila pneumoniae. A — Chlamydophila elementary body. B — Lung cell. 2 — Chlamydophila enters the cell. 3 — Elementary body becomes a reticulate body. 4 — Replication. 5 — Reticulate bodies become elementary bodies and are released to infect other cells.

Chlamydophila pneumoniae is a small gram negative bacterium (0.2 to 1 organism or in a new host. Thus, the lifecycle of C. pneumoniae is divided between the elementary body, which is able to infect new hosts but cannot replicate, and the reticulate body, which replicates but is not able to cause new infection.

Diseases

C. pneumoniae is a common cause of pneumonia around the world; it is typically acquired by otherwise-healthy people and is a form of community-acquired pneumonia. Its treatment and diagnosis are different from historically recognized causes, such as Streptococcus pneumoniae.[9] Because it does not gram stain well, and because C. pneumoniae bacteria is very different from the many other bacteria causing pneumonia (in the earlier days, it was even thought to be a virus), the pneumonia caused by C. pneumoniae is categorized as an "atypical pneumonia".

One meta-analysis of serological data comparing prior C. pneumoniae infection in patients with and without lung cancer found results suggesting prior infection was associated with an increased risk of developing lung cancer.[10][11][12]

In research into the association between C. pneumoniae infection and atherosclerosis and coronary artery disease, serological testing, direct pathologic analysis of plaques, and in vitro testing suggest infection with C. pneumoniae is a significant risk factor for development of atherosclerotic plaques due to the fact that it causes chronic shortages of micro-nutrients such as Potassium, Magnesium, Zinc, Vitamins A, B1, B2, B6, B9 , B12 ,C ,D ,K1 and K2. Most people with C pneumoniae will also develop Prostatitis due to these deficiencies. C. pneumoniae infection increases adherence of macrophages to endothelial cells in vitro and aortas ex vivo.[13] However, most current research and data are insufficient and do not define how often C. pneumoniae is found in atherosclerotic or normal vascular tissue, nor does it allow for determining how or wheather C. pneumoniae has a causative effect on atheroma formation.[14]

C. pneumoniae has also been found in the cerebrospinal fluid of patients diagnosed with multiple sclerosis.[15]

C. pneumoniae infection was first associated with wheezing, asthmatic bronchitis, and adult-onset asthma in 1991.[16] Subsequent studies of bronchoalveolar lavage fluid from pediatric patients with asthma and also other severe chronic respiratory illnesses have demonstrated that over 50 percent had evidence of C. pneumoniae by direct organism identification.[17][18] C. pneumoniae infection triggers acute wheezing, if it becomes chronic then it is diagnosed as asthma.[19] These observations suggest that acute C. pneumoniae infection is capable of causing protean manifestations of chronic respiratory illness which lead to asthma.

Macrolide antibiotic treatment can improve asthma in a subgroup of patients that remains to be clearly defined. Macrolide benefits were first suggested in two observational trials[20][21] and two randomized controlled trials[22][23] of azithromycin treatment for asthma. One of these RCTs[23] and another macrolide trial[24] suggest that the treatment effect may be greatest in patients with severe, refractory asthma. These clinical results correlate with epidemiological evidence that C. pneumoniae is positively associated with asthma severity[25] and laboratory evidence that C. pneumoniae infection creates steroid-resistance.[26] A recent meta analysis of 12 RCTs of macrolides for the long term management of asthma found significant effects on asthma symptoms, quality of life, bronchial hyper reactivity and peak flow but not FEV1.[27] Evidence from macrolide RCTs of patients with uncontrolled severe and refractory asthma will be critical in defining the role of macrolides in asthma.

Vaccine research

There is currently no vaccine to protect against Chlamydophila pneumoniae. Identification of immunogenic antigens is critical for the construction of an efficacious subunit vaccine against C. pneumoniae infections. Additionally, there is a general shortage worldwide of facilities which can identify / diagnose Chlamydia pneumoniae.

References

  1. ^ Everett, K. D. E.; Bush, R. M.; Andersen, A. A. (1999). "Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms". International Journal of Systematic Bacteriology 49 (2): 415–440.  
  2. ^ Chlamydophila pneumoniae at the US National Library of Medicine Medical Subject Headings (MeSH)
  3. ^ http://pathmicro.med.sc.edu/mayer/chlamyd.htm
  4. ^ "www.ncbi.nlm.nih.gov". Retrieved 2009-01-27. 
  5. ^ Appelt DM, Roupas MR, Way DS; et al. (2008). "Inhibition of apoptosis in neuronal cells infected with Chlamydophila (Chlamydia) pneumoniae". BMC Neurosci. 9: 13.  
  6. ^ Kalman, S.; Mitchell, W.; Marathe, R.; Lammel, C.; Fan, J.; Hyman, RW.; Olinger, L.; Grimwood, J.; et al. (Apr 1999). "Comparative genomes of Chlamydia pneumoniae and C. trachomatis". Nat. Genet. 21 (4): 385–9.  
  7. ^ Lang, B. R., Chlamydia pneumonia as a differential diagnosis? Follow-up to a case report on progressive pneumonitis in an adolescent, Patient Care, Sept. 15, 1991
  8. ^ Little, Linda, Elusive pneumonia strain frustrates many clinicians, Medical Tribune, p. 6, September 19, 1991
  9. ^ Pignanelli S, Shurdhi A, Delucca F; et al. (2009). "Simultaneous use of direct and indirect diagnostic techniques in atypical respiratory infections from Chlamydophila pneumoniae and Mycoplasma pneumoniae". J. Clin. Lab. Anal. 23 (4): 206–9.  
  10. ^ Zhan P, Suo LJ, Qian Q; et al. (March 2011). "Chlamydia pneumoniae infection and lung cancer risk: A meta-analysis". Eur. J. Cancer 47 (5): 742–7.  
  11. ^ Mager, DL (2006). "Bacteria and cancer: cause, coincidence or cure? A review". Journal of Translational Medicine 4 (1): 14.  
  12. ^ Littman, A. J. (2005). "Chlamydia pneumoniae and Lung Cancer: Epidemiologic Evidence". Cancer Epidemiology Biomarkers & Prevention 14 (4): 773–778.  
  13. ^ Takaoka N, Campbell LA, Lee A, Rosenfeld ME, Kuo CC; Campbell; Lee; Rosenfeld; Kuo (February 2008). "Chlamydia pneumoniae infection increases adherence of mouse macrophages to mouse endothelial cells in vitro and to aortas ex vivo". Infection and Immunity 76 (2): 510–4.  
  14. ^ Mussa FF, Chai H, Wang X, Yao Q, Lumsden AB, Chen C; Chai; Wang; Yao; Lumsden; Chen (June 2006). "Chlamydia pneumoniae and vascular disease: an update". J. Vasc. Surg. 43 (6): 1301–7.  
  15. ^ Sriram S, Stratton CW, Yao S; et al. (1999). "Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis". Annals of Neurology 46 (1): 6–14.  
  16. ^ Hahn DL, Dodge R, Golubjatnikov R; Dodge; Golubjatnikov (1991). "Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis and adult-onset asthma". JAMA 266 (2): 225–230.  
  17. ^ Schmidt SM, Muller CE, Bruns R; et al. (2001). "Bronchial Chlamydia pneumoniae infection, markers of allergic inflammation and lung function in children". Pediatr. Allergy Immunol. 12 (5): 257–265.  
  18. ^ Webley WC, Salva PS, Andrzejewski C; et al. (2005). "The bronchial lavage of pediatric patients with asthma contains infectious Chlamydia". Am. J. Respir. Crit. Care Med. 171 (10): 1083–1088.  
  19. ^ Hahn DL, McDonald R; McDonald (1998). "Can acute Chlamydia pneumoniae infection initiate chronic asthma?". Ann. Allergy Asthma Immunol. 81 (4): 339–344.  
  20. ^ Hahn DL (1995). "Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial". J. Fam. Pract. 41 (4): 345–351.  
  21. ^ Hahn DL, Schure A, Patel K; et al. (2012). "Chlamydia pneumoniae-specific IgE is prevalent in asthma and is associated with disease severity". PLoS ONE 7 (4): e35945.  
  22. ^ Hahn DL, Plane MB, Mahdi OS; et al. (2006). "Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma". PLoS Clinical Trials 1 (2): e11.  
  23. ^ a b Hahn DL, Grasmick M, Hetzel S; et al. (2012). "Azithromycin for bronchial asthma in adults: An effectiveness trial". J. Am. Board Fam. Med. 25 (4): 442–459.  
  24. ^ Simpson JL, Powell H, Boyle MJ; et al. (2008). "Clarithromycin targets neutrophilic airway inflammation in refractory asthma". Am. J. Respir. Crit. Care Med. 177 (2): 148–155.  
  25. ^ von Hertzen L, Vasankari T, Liippo K; et al. (2002). "Chlamydia pneumoniae and severity of asthma". Scand. J. Infect. Dis. 34 (1): 22–27.  
  26. ^ Cho YS, Kim TB, Lee TH; et al. (2005). "Chlamydia pneumoniae infection enhances cellular proliferation and reduces steroid responsiveness of human peripheral blood mononuclear cells via a tumor necrosis factor-alpha-dependent pathway". Clinical & Experimental Allergy 35 (12): 1625–1631.  
  27. ^ Reiter, J; et al. (2013). "Macrolides for the long-term management of asthma - a meta-analysis of randomized clinical trials". Allergy 68 (8): 1040–9.  

External links

  • Chlamydia Pneumoniae cpnhelp.org
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.